Table 2.
Serum chemistries, insulin resistance and liver biopsy grade.
| Clinical Parameter | Healthy | NASH |
|---|---|---|
| Creatinine (mg/dL) | 0.82 (0.14) | 0.80 (0.22) |
| ALT (U/L) | 33 (11) | 75 * (36) |
| ALP (U/L) | 63 (13) | 80 * (14) |
| Albumin (g/dL) | 4.3 (0.3) | 4.5 (0.4) |
| Total Bilirubin (mg/dL) | 0.64 (0.22) | 0.81 (0.29) |
| Cholesterol (mg/dL) | 189 (40) | 190 (48) |
| Triglycerides (mg/dL) | 91 (46) | 253 * (98) |
| HDL (mg/dL) | 68 (26) | 37 * (5) |
| LDL, calculated (mg/dL) | 102 (34) | 101 (47) |
| Fasting Glucose (mg/dL) | 86 (8) | 124 * (16) |
| Serum Insulin (μIU/mL) | 8 (3) | 40 * (27) |
| HOMA-IR | 2 (1) | 12 * (9) |
| Total NAS Score | N/A | 5 (4-6) |
| Steatosis | N/A | 2 (1-3) |
| Hepatocyte Ballooning | N/A | 2 (1-3) |
| Inflammation | N/A | 1 (0-2) |
| Fibrosis | N/A | 1 (0-3) |
| NAS + Fibrosis | N/A | 7 (4-8) |
Data presented as mean (SD); biopsy scoring presented as median (range)
ALT; alanine aminotransferase
ALP; alkaline phosphatase
HDL; high-density lipoprotein cholesterol
LDL; low-density lipoprotein cholesterol
NAS: non-alcoholic fatty liver disease activity score
HOMA-IR; homeostasis model for assessing insulin resistance
N/A; not applicable
*
P<0.05, Student's two-tailed t-test comparing healthy subjects to patients with NASH